German corporation Bayer has announced that its four most promising drugs, led by newly-launched anti-clotting pill Xarelto, may account for combined annual sales of as much as $6.5 billion, according to a Reuters report.
The report says Bayer’s healthcare division is aiming for sales of roughly $26.2 billion in 2014, up from $22.4 billion last year.
The company said prescription drug sales were set to rise to about $15 billion by 2014, up 16 percent from 2011, fueled largely by new product launches.
Thousands of plaintiffs in lawsuits against Bayer allege that the corporation’s hurry to put drugs on the market without adequate testing and warnings harmed patients. For example, the Yaz/Yasmin/Beyaz litigation involves birth control pills that contain the synthetic hormone drospirenone.
Ironically (given that Bayer’s new flagship product, Xarelto, is an anti-clotting drug), drospirenone increases the risk of potentially fatal blood clots, according to several studies. Other health concerns associated with Yaz, Yasmin, and Beyaz birth control pills include gallbladder disease, strokes and pulmonary embolism.
Women who have suffered injury as a result of taking Yaz, Yasmin, Beyaz or Ocella can contact Lopez McHugh for a free consultation. Call today because if you wait too long, you may be barred from recovering for your injuries by your state’s time limits.